Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy is a prescription injectable medication manufactured by Novo Nordisk that contains semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes. Since its 2021 FDA approval for weight management, demand has outpaced supply, leaving many patients on waitlists or unable to access the medication. PlexusDx offers a practical alternative: compounded semaglutide injections prepared by licensed 503A pharmacies, available to all 50 states without insurance requirements.

Who Manufactures Wegovy and How It Works

Novo Nordisk, a Danish pharmaceutical company, is the sole manufacturer of Wegovy. The company developed semaglutide as a once-weekly injectable GLP-1 agonist that mimics glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. When you inject Wegovy, it binds to GLP-1 receptors in your brain and digestive system, which reduces hunger signals, slows stomach emptying, and increases feelings of fullness. Clinical trials showed that patients using semaglutide lost an average of 15-18% of their starting body weight over 68 weeks.

The medication is delivered as a prefilled pen injected once per week under the skin. Novo Nordisk manufactures Wegovy in doses ranging from 0.25 mg to 2.4 mg, with patients typically starting at a low dose and gradually increasing as their body adjusts. The branded version carries a price tag between $900 and $1,400 per month without insurance, which has created significant barriers to access for many people seeking GLP-1 therapy.

Why Wegovy Supply Is Limited and Hard to Access

Since Novo Nordisk received FDA approval for Wegovy in 2021, the medication has faced consistent supply shortages driven by unprecedented demand. Celebrities and social media influencers have amplified interest in GLP-1 therapy, while type 2 diabetics continue to use semaglutide under its original brand name, Ozempic. Manufacturing capacity at Novo Nordisk facilities has struggled to meet global demand, resulting in frequent backorders and waitlists that can stretch for months.

Insurance coverage for Wegovy remains inconsistent because it is classified as a weight management medication rather than a diabetes treatment. Many insurance plans either deny coverage entirely or require proof of medical necessity and multiple prior authorization steps. For those without insurance or with plans that refuse to cover weight loss medications, the out-of-pocket cost of $900-$1,400 monthly creates another barrier to treatment initiation and continuation.

Compounded Semaglutide as a Practical Alternative

PlexusDx offers compounded semaglutide injections prepared by licensed 503A compounding pharmacies, providing patients with an accessible alternative to branded Wegovy. Compounding pharmacies take FDA-approved semaglutide powder and create custom injectable solutions under strict quality standards and pharmacy oversight. PlexusDx compounded semaglutide starts at $149 per month with no dose-dependent price increases—your dose may need to go up, but your price won't.

The active ingredient in compounded semaglutide is chemically identical to Wegovy, though the delivery formulation and manufacturing process differ. Patients can begin treatment immediately without waitlists, and PlexusDx serves all 50 states without requiring health insurance. HSA and FSA accounts are eligible for payment, which can reduce out-of-pocket expenses further. Your PlexusDx provider determines the appropriate starting dose and titration schedule based on your medical history and goals.

Personalized GLP-1 Therapy Through Genetic Insights

PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway genetic assessment that identifies how your body may respond to GLP-1 medications. The test analyzes key genetic variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313, which influence appetite regulation, metabolic rate, and weight loss response. By mapping 14 biological pathways and 150+ genetic insights, PlexusDx helps clinicians tailor your medication choice and dosing strategy to your unique genetic profile.

If your genetics show strong GLP1R receptor sensitivity, you may achieve excellent results at lower doses of semaglutide. Alternatively, if genetic data suggests dual-pathway activation would benefit you more, PlexusDx offers GLP-Squared Injection, which combines semaglutide and tirzepatide for synergistic appetite control. The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment, allowing you to refine your therapy based on science rather than trial and error.

What You Should Know Before Starting Semaglutide

Before starting any GLP-1 medication, inform your PlexusDx provider about any personal or family history of thyroid cancer, multiple endocrine neoplasia type 2 (MEN2), pancreatitis, gallbladder disease, or severe kidney problems. Semaglutide is not recommended during pregnancy or if you are planning to become pregnant within three months. Common side effects during the initial weeks include nausea, vomiting, constipation, and diarrhea, most of which decrease as your body adjusts to the medication.

Your dose will increase gradually over weeks according to a standardized titration schedule, which helps minimize gastrointestinal side effects and allows your body to adapt safely. Regular follow-up appointments with your PlexusDx clinician ensure your treatment is working effectively and any concerns are addressed promptly. Once you reach your maintenance dose, most patients report significantly reduced appetite, improved energy levels, and sustainable weight loss over several months.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide from PlexusDx the same as Wegovy?

Compounded semaglutide contains the same active pharmaceutical ingredient as Wegovy, but is prepared by licensed 503A compounding pharmacies rather than manufactured by Novo Nordisk. Both deliver semaglutide via injection, though the formulation and delivery device differ. PlexusDx compounded semaglutide is an accessible alternative for patients unable to access or afford branded Wegovy.

How much weight can I expect to lose on semaglutide?

Clinical trials demonstrate that patients on semaglutide lose an average of 15-18% of their starting body weight over 68 weeks, though individual results vary based on genetics, diet, exercise, and medication adherence. Some patients achieve greater weight loss, while others may see more modest reductions. PlexusDx's Precision Peptide Genetic Test can help predict your likely response based on your unique genetic profile.

What does PlexusDx compounded semaglutide cost compared to Wegovy?

PlexusDx compounded semaglutide starts at $149 per month with flat pricing across all dose levels, compared to Wegovy's typical cost of $900-$1,400 monthly without insurance. PlexusDx requires no insurance, no membership fees, and accepts HSA/FSA payments. Your dose may increase during treatment, but your monthly price remains the same.

What are the most common side effects of semaglutide?

Nausea, vomiting, constipation, and diarrhea are the most frequently reported side effects, especially during the first few weeks of treatment. These symptoms typically diminish as your body adjusts. More serious but rare side effects include pancreatitis and thyroid concerns; notify your PlexusDx provider immediately if you experience severe abdominal pain or difficulty swallowing.

How does the Precision Peptide Genetic Test help personalize my semaglutide treatment?

PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to predict how your body responds to GLP-1 medications. Results guide your clinician in choosing between semaglutide alone or dual-compound options like GLP-Squared, and inform optimal dosing strategies based on your genetic predispositions.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves